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AMORPHOUS SOLID DISPERSIONS AND SOLVATES OF ACORAMIDIS HCl

Srinivas Oruganti, Sarvesh Kumar, Mohan Kumar Kottur and Saikat Sen
Dr. Reddy’s Institute of Life Sciences, University of Hyderabad Campus, Gachibowli,
Hyderabad 500046, India

Abstract:
The present application relates to solid state forms of Acoramidis HCl and processes for
preparation thereof.

Background:
The drug compound Acoramidis is chemically known as 3-(3-(3,5-dimethyl-1H-pyrazol-4yl)propoxy)-4-fluorobenzoicacid and has structure depicted by Formula I. This molecule is
under development by Eidos Therapeutics for transthyretin stabilizer (cardiomyopathy).

Crystalline solids normally require a significant amount of energy for dissolution due to their
highly organized, lattice like structures. For example, the energy required for a drug molecule
to escape from a crystal is more than from an amorphous or a non-crystalline form. It is known
that the amorphous forms in a number of drugs exhibit different dissolution characteristics; and
in some cases, different bioavailability patterns compared to the crystalline form. For some
therapeutic indications, one bioavailability pattern may be favored over another. Therefore, it
is desirable to have amorphous forms of drugs with high purity to meet the needs of regulatory
agencies and also highly reproducible processes for their preparation.

In view of the above, it is therefore, desirable to have access to stable amorphous form of
Acoramidis HCl. The amorphous form provided herein is at least stable under ordinary stability
conditions with respect to purity, storage and is free flowing powder.

Published by Technical Disclosure Commons, 2022

2

Defensive Publications Series, Art. 5506 [2022]

Amorphous solid dispersions of drugs are generally known to improve the stability and
solubility of drug products. However, some of such amorphous solid dispersions are found to
be unstable over time. Amorphous solid dispersions of drugs tend to convert to crystalline
forms over time, which can lead to improper dosing due to differences of the solubility of
crystalline drug material compared to amorphous drug material. The present invention,
however provides stable amorphous solid dispersions of Acoramidis HCl with improved
solubility. Moreover, the present invention provides amorphous solid dispersions of
Acoramidis HCl which may be reproduced easily and is amenable for processing into a dosage
form.

Examples
Example 1: Amorphous solid dispersion of Acoramidis HCl with Copovidone (1:1 w/w)
Acoramidis hydrochloride (200 mg) and Copovidone (200 mg) were dissolved in 20%
methanol-DCM (15 mL). The solution obtained was filtered, concentrated under reduced
pressure at 45 °C and dried under vacuum to obtain a sticky off-white solid (352 mg, purity:
99.46% by HPLC). 100 mg of this solid obtained was mixed with Syloid 244 FP (100 mg) and
ground together to obtain a free flowing solid. Figure 1 is an illustrative X-ray powder
diffraction pattern of this premix obtained.

Example 2: Amorphous solid dispersion of Acoramidis HCl with PVP K-30 (1:1 w/w)
Acoramidis hydrochloride (150 mg) and PVP K-30 (150 mg) were dissolved in 20% MethanolDCM (15 mL). The solution obtained was filtered, concentrated under reduced pressure at 45
°C and dried under vacuum to obtain a sticky off-white solid (252 mg, purity: 99.50% by
HPLC). 75 mg of this solid obtained was mixed with Syloid 244 FP (75 mg) and ground
together to obtain a free flowing solid. Figure 2 is an illustrative X-ray powder diffraction
pattern of this premix obtained.

Example 3: Amorphous solid dispersion of Acoramidis HCl with HPC (1:2 w/w)
Acoramidis hydrochloride (100 mg) and HPC (200 mg) were dissolved in 20% Methanol-DCM
(30 mL). The solution obtained was filtered, concentrated under reduced pressure at 45 °C and
dried under vacuum to obtain an off-white sticky fluffy solid (228 mg, purity: 99.35% by
HPLC). 75 mg of this solid obtained was mixed with Syloid 244 FP (75 mg) and ground
together to obtain a free flowing solid. Figure 3 is an illustrative X-ray powder diffraction
pattern of this premix obtained.
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Example 4: Amorphous solid dispersion of Acoramidis HCl with HPMC (1:2 w/w)
Acoramidis hydrochloride (100 mg) and HPMC (200 mg) were dissolved in 20% MethanolDCM (20 mL). The solution obtained was filtered, concentrated under reduced pressure at 45
°C and dried under vacuum to obtain an off-white sticky fluffy solid (225 mg, purity: 99.37%
by HPLC). 100 mg of this solid obtained was mixed with Syloid 244 FP (100 mg) and ground
together to obtain a free flowing solid. Figure 4 is an illustrative X-ray powder diffraction
pattern of this premix obtained.

Example 5: DMF solvate of Acoramidis HCl
Acoramidis hydrochloride (200 mg) was dissolved in DMF (10 mL) at RT. The solution was
filtered and concentrated under reduced pressure at 70 °C. The solid obtained was under
vacuum at 27 °C for 15-20 min to obtain the title compound. Details are given below.
1

H NMR (DMSO-d6, 400 MHz): δ 1.93-1.90 (m, 2H), 2.23 (s, 6H), 2.57 (t, J = 7.2 Hz, 2H),

2.73 (s, 2.46H, DMF), 2.89 (s, 2.52H, DMF), 4.07 (t, J = 6.4 Hz, 2H), 7.34 (dd, J = 10.8, 8.4
Hz, 1H), 7.56 (ddd, J = 8.4, 4.4, 2.0 Hz, 1H), 7.61 (dd, J = 8.4, 1.6 Hz, 1H), 7.95 (s, 0.76H,
DMF)

Yield

Purity

Appearance

PXRD

TGDTA

188 mg

95.64% (by HPLC)

Off-white solid

Figure 5

Figure 6
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Figure 1: PXRD of Amorphous solid dispersion of Acoramidis HCl with Copovidone (1:1 w/w)

Figure 2: PXRD of Amorphous solid dispersion of Acoramidis HCl with PVP K-30 (1:1 w/w)
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Figure 3: PXRD of Amorphous solid dispersion of Acoramidis HCl with HPC (1:2 w/w)

Figure 4: PXRD of Amorphous solid dispersion of Acoramidis HCl with HPMC (1:2 w/w)
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Figure 5: PXRD of DMF solvate of Acoramidis HCl

Figure 6: TGDTA of DMF solvate of Acoramidis HCl
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